Reid Huber

Reid Huber has been working in the field since 2014, when they became a Director at Bellicum Pharmaceuticals, Inc. In 2017, they became a Director at The Andrew McDonough B+ Foundation. In 2018, they became a Partner at Third Rock Ventures. In 2019, they became a Board Observer at insitro and a Director at Tango Therapeutics. In 2020, they became a Director at Eastern New Enlgand Board of the American Cancer Society and a Director at Partners HealthCare, Innovation Growth Board. In 2021, they became a Director at Terremoto Biosciences, a Director at Asher Biotherapeutics, and a Director and CEO at MOMA Therapeutics.

Reid Huber received a PhD in Molecular Genetics/Biochemistry from Washington University School of Medicine in St. Louis between 1994 and 1998. Reid also attained a BS in Molecular Genetics/Biochemistry from Murray State University between 1991 and 1994.